[{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mesoblast"},{"orgOrder":0,"company":"Biotron","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotron\u2019s Compound BIT036 as an antiviral for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Biotron"},{"orgOrder":0,"company":"Novotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novotech Wins Cro Contract For Komipharm Coronavirus Covid-19 Clinical Trial In South Korea\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Novotech"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Implicit Bioscience"},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma Provides Development Update on Spl7013 Nasal Spray for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Large molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Starpharma"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for\u00a0COVID-19 Vaccine and Cancer Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"EnGeneIC"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV™ in combination with its anti-cancer drugs and COVID-19 vaccine.
Lead Product(s):
EnGeneIC Dream Vector,Undisclosed
Based on discussions with regulators, the company expects to be able to expedite approval of a SPL7013 nasal spray by leveraging existing nonclinical and clinical data of Starpharma’s currently approved and marketed products.
The trial will assess if IC14 can temper the immune system’s response to coronavirus infection of the lungs, thus preventing dangerous levels of inflammation.
A clinical study conducted in China reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.